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ARTICLE
Discovery of driver non-coding splice-site-creating
mutations in cancer
Song Cao1,2, Daniel Cui Zhou 1,2, Clara Oh1,2, Reyka G. Jayasinghe1,2, Yanyan Zhao1, Christopher J. Yoon1,2,
Matthew A. Wyczalkowski 1,2, Matthew H. Bailey 1,2, Terrence Tsou 1,2, Qingsong Gao1,2,
Andrew Malone 1, Sheila Reynolds3, Ilya Shmulevich3, Michael C. Wendl2,4,5, Feng Chen1,6✉ & Li Ding1,2,4,6✉
Non-coding mutations can create splice sites, however the true extent of how such somatic
non-coding mutations affect RNA splicing are largely unexplored. Here we use the MiSplice
pipeline to analyze 783 cancer cases with WGS data and 9494 cases with WES data,
discovering 562 non-coding mutations that lead to splicing alterations. Notably, most of these
mutations create new exons. Introns associated with new exon creation are significantly
larger than the genome-wide average intron size. We find that some mutation-induced
splicing alterations are located in genes important in tumorigenesis (ATRX, BCOR, CDKN2B,
MAP3K1, MAP3K4, MDM2, SMAD4, STK11, TP53 etc.), often leading to truncated proteins and
affecting gene expression. The pattern emerging from these exon-creating mutations sug-
gests that splice sites created by non-coding mutations interact with pre-existing potential
splice sites that originally lacked a suitable splicing pair to induce new exon formation. Our
study suggests the importance of investigating biological and clinical consequences of
noncoding splice-inducing mutations that were previously neglected by conventional anno-
tation pipelines. MiSplice will be useful for automatically annotating the splicing impact of
coding and non-coding mutations in future large-scale analyses.
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Large-scale studies, such as The Cancer Genome Atlas(TCGA), have identified numerous driver mutations incoding regions using whole-exome sequencing (WES) data,
but most non-coding sequences still lack characterization. Non-
coding drivers have started to emerge from whole-genome
sequencing (WGS) data. For instance, recurrent mutations in
the TERT promoter have been found in gliomas, melanoma, and
bladder cancers1–3. Importantly, these are associated with poor
clinical outcomes in bladder cancer3. Other drivers in promoter
regions and untranslated regions (UTRs) have been found in
recent pan-cancer WGS studies4–6 and by individual WGS stu-
dies on melanoma7, breast cancer8, and renal cell cancer9,
including mutations in PLESHS1, WDR74, and SDHD. A few
studies have also reported how mutations functionally affect RNA
splicing and impact human disease10–13. For example, an intronic
germline mutation in COL6A1 creates a new exon associated with
collagen dystrophy12. However, the true extent of how such
somatic non-coding mutations affect RNA splicing in tumors
remains largely unknown.
The identification and analysis of non-coding events and the
identification of contributing drivers are crucial, open problems
in cancer genomics. Some tools, such as OncoDriveFML14 and
LARVA15, predict mutation impact by leveraging data from
ENCODE, but their general frameworks are unable to identify
more specific phenomena, such as splicing perturbations. Here,
we apply MiSplice (Mutation-Induced Splicing), a bioinformatics
tool that can identify mutation-induced splice forms in cancer
using a combination of WGS and RNA-sequencing (RNA-Seq)
data16, to investigate the splicing alteration from non-coding
mutations. We systematically evaluate how somatic mutations in
non-coding regions create splice alterations in 783 WGS samples
and 9494 WES samples from TCGA, identifying 562 non-coding
splice-site-creating mutations (nc-SCMs). Many of them reside in
important cancer-related genes, such as ATRX, BCOR, CDKN2B,
MAP3K1, MAP3K4, MDM2, SMAD4, STK11, and TP53. We also
discover alternative splicing phenomena enriched in non-coding
regions, such as new exon creation being the dominant splice
alteration event.
Results
MiSplice pipeline, simulation, power assessments, and bench-
mark. MiSplice is a fully automated and highly parallelized
pipeline that applies analytical and statistical processes to discover
mutation-induced splicing events, which has been applied to
coding mutations (see “Methods”)16. Here, we extend it to non-
coding mutations. It consists of a processing module for junction
discovery and three successive modules for filtering based on
proximity to known polymorphic genes/junctions, coverage and
supporting read requirements, and case/control comparisons
(Supplementary Fig. 1). MiSplice jointly analyzes WGS and RNA-
Seq data, scanning the transcriptome for statistically significant
non-canonical sequence junctions supported by expression evi-
dence. It is parameterized with a number of supporting reads (M),
minimum quality of the reads (Q), mutation–junction distance
(N), and fraction of supporting reads (k).
We conducted in silico simulations to estimate the sensitivity
of the MiSplice pipeline under various coverage depths, mixture
read fractions, and mutation distances. To further evaluate the
performance of MiSplice pipeline (v1.1), we generated two
simulated RNA-Seq data sets having average coverages of 100×
and 200× to estimate the sensitivity of MiSplice when run using
its heuristic ranking algorithm (processing module 3 in
Supplementary Fig. 1). Specifically, we mixed reads generated
from altered junction templates with reads from reference
junction templates at various ratios, resulting in nine test sets
having read mixture fractions ranging from 0.1 to 0.5 in
increments of 0.05. We then used MapSplice17 for alignment. A
benchmark test shows that MiSplice can identify non-canonical
junctions with sensitivity >90%, given 200× coverage for the non-
canonical junctions and read mixture fraction >0.2 (Fig. 1a).
More broadly, at 200× coverage, MiSplice’s sensitivity ranges
from 0.74 to 0.97 as the mixing ratio changes from 0.1 to 0.5. As
coverage increases, we observe an appreciable increase in
sensitivity, resulting from the overall higher number of
junction-spanning reads.
In processing module 3, MiSplice can alternatively evaluate
candidate sites using a binomial hypothesis test. Here, the null
hypothesis is that the junction allele fraction (JAF), which is the
ratio of the number of reads supporting a site versus total number
of reads at that genomic location, is indistinguishable from a
value obtained by chance. Power estimates (see “Methods”) can
be used to quantify the necessary read depth for a given effect
size. Figure 1b shows curves for standard 80%, 90%, and 95%
power thresholds plotted as functions of alternative JAF versus a
null hypothesis with JAF of 5%. MiSplice is well powered given
sufficient coverage, for example, requiring ~150× coverage for
detecting 10% JAF events at 80% power. Following these
assessments, we used MiSplice to examine 783 samples with
WGS mutation data and 9494 samples with WES, finding 562 nc-
SCMs (Fig. 1c); see Data availability.
Compared to previous studies16,18, the current study focuses
on the comprehensive discovery of nc-SCMs. We removed coding
mutations annotated as Splice_Site, Missense, Nonsense, Non-
stop, In_Frame, and Frame_Shift to focus on non-coding
mutations. We compared nc-SCMs in the present study and
three previous studies13,16,18, finding that 150 nc-SCMs from
WGS and 178 nc-SCMs from WES are unique and not reported
in these previous studies. Our previous work16 focused on
coding-region mutations and has little overlap with the current
study (5% overlapping with nc-SCMs from WGS data and 11%
overlapping with nc-SCMs from WES). Shiraishi et al.18
discovered splice-associated variants (SAVs) from WES data
using SAVnet and their results show ~44 and 9% overlap with nc-
SCMs from WES and WGS data in the present study,
respectively. The PCAWG Consortium13 also used SAVnet to
discover SAVs from WGS, with respective overlaps to this study
of ~5 and 33%. Overall 66 and 48% of nc-SCMs from respective
WGS and WES data sets are uniquely reported in this study.
We further estimated the sensitivity and specificity for
MiSplice16 and SAVnet18 based on the nc-SCMs found in TCGA
WGS samples in the current study and the previous study13.
Manual review by Integrative Genomics Viewer (IGV) reveals 111
true hits over 240 nc-SCMs for SAVnet and 228 true hits over 281
nc-SCMs from MiSplice (see “Methods” and the following
section), of which 79 nc-SCMs are common to both pipelines.
Seventy-six out of the 79 nc-SCMs are true hits. Based on these
numbers, we estimated that the sensitivity and specificity for
SAVnet are ~46% and 42%, respectively, and for MiSplice are
87% and 81%, respectively. For nc-SCMs uniquely reported by
SAVnet, we observed a high false-positive rate of ~78%. For the
79 nc-SCMs reported by both SAVnet and MiSplice, the false-
positive rate was very low (~4%), suggesting more confident calls
when reported by both tools. For the unique calls reported by
MiSplice, we observed a high false-positive rate (25%). The
observed difference in the nc-SCM calls reflects underlying
differences in strategy and algorithm design between SAVnet and
the MiSplice pipeline. SAVnet aims to predict different splicing-
associated events, including exon skipping, intron retention, and
splice-site-creating events. Conversely, MiSplice is focused on
splice-site-creating events. Also, for the detection of SCMs,
SAVnet restricts somatic variants to local positions of newly
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created splice site or canonical splice site, that is, −3 to +6 for
donor and −1 to +6 for acceptor18. MiSplice is designed for
broader positional scope, namely, within the 20-bp window of the
splice site that typically affects the splice score16. This larger
search space enables MiSplice to detect more nc-SCMs that fall
into other splicing regions near the splice site. Through this
comparison, we noticed that some newly created splice sites could
be far away from the mutation when that mutation is close to the
canonical splice site, such that the canonical splice site is
disrupted. SAVnet captures this scenario as long as the mutation
is close to the canonical splice site. However, since MiSplice
implements a 20-bp cut-off between the mutation and the newly
created splice site, it misses these unique calls predicted by
SAVnet, which fall in this category. In addition, in MiSplice, we
incorporated a method for calculating splice scores, which enables
improved characterization of these newly created splice sites.
Discovery of nc-SCMs from 783 TCGA whole-genome data.
We applied MiSplice to 783 TCGA samples having both WGS
and RNA-Seq data (Fig. 1c) to identify non-coding mutations
leading to splice alterations. Here, we chose M= 5, Q= 20, N=
20, and k= 0.05, based on power analyses (see “Methods”). We
found 281 non-coding mutations associated with splice altera-
tions, which were manually reviewed with IGV19; see “Methods.”
Each splice junction had at least five supporting reads. In addi-
tion, sites with spliced-in mutations were required to have at least
30% of reads supporting the junction. Consistent with our pre-
vious publication, we defined spliced-in mutations as mutations
that were found in RNA-Seq reads supporting the junction16. The
heuristic 30% cut-off that we set is to further support the asso-
ciation between mutation and the junction in addition to the case
and control test. For spliced-in mutations, we also added a
specific manual review to check that reads, which cover both
junction and mutation site, contain the specific mutation; see
“Methods.” Two hundred and twenty-eight sites passed these
manual review criteria (Supplementary Data 1), of which 189
were found to create splice forms in intronic and UTR regions, 14
in 5′ flanking regions, 6 in RNAs, and 7 in intergenic regions
(IGRs) (Fig. 2a, b). These manual review statistics suggest a
specificity of 81%.
We further categorized these events into seven groups
according to their splicing impact: new exon creation, exon
extension, exon shrinkage, exon splitting, gene fusion, new
transcript, and complex events (Fig. 2a, b). Exon creation is
especially notable since it has been rarely reported previously13,
but here accounts for 109 of the total 228 events (47%). Exon
extension follows with 71 events. We also detected 22 new
transcript, 9 exon splitting, 6 complex, 8 exon shrinkage, and 3
fusion events, where the complex events category is defined as a
combination of multiple events, such as exon shrinkage and new
exon (Fig. 2a, b). We found that the lengths of introns in which
exon extension and shrinkage occur are comparable to the
genome-wide average (~3000 bp) (Fig. 2c). However, introns with
exon-creating mutations are generally an order of magnitude
larger, suggesting that longer introns are appreciably more biased
toward new exon creation (Fig. 2c and “Methods”).
Characteristics of non-coding splice alterations. We used
MaxEntScan20 to estimate the splice strength of the reference and
mutant splice sites (“Methods”). For both donor and acceptor sites,
we observed equal or higher splicing scores in the junctions with
mutations compared to the reference (mean scores of 3.48 and 0.88,
respectively) (Fig. 3a). On two occasions, we found sites with rela-
tively low splicing scores, but these are attributed to the usage of non-
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Fig. 1 Benchmark test of MiSplice pipeline and sample set. a Sensitivity curves derived by simulating various coverage levels and mutation distances
plotted as a function of splice allele fraction (ratio of non-canonical junction reads over canonical junction reads). b Required junction read coverage to
achieve sufficient power. c Sample data set processed by MiSplice pipeline. Source data are provided as a Source Data file.
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canonical splice sites (Fig. 3a and Supplementary Data 1). Moreover,
there are peaks for mutations near the splice site at −1 and +2
positions for donors and −1 position for acceptors (Fig. 3a).
Regarding creation of a new exon between two canonical
exons, a mutation converts a nearby sequence to a functioning
primary splice site (PSS), which in turn recruits an activated mate
site (AMS) elsewhere in the intron (Fig. 3b). The PSS and AMS
form the bounds of the new exon. AMSs have high splicing
scores, averaging 5.13, which suggest that they were already
primed for splicing but simply lacked a suitable splicing partner
in the reference sequence (Fig. 3b, c). Supplementary Figure 3
shows consensus sequences in donor and acceptor splice sites for
both the primary and activated mate sites. The percentages of T’s
in the −13 and −8 positions and G’s in the −3 position all
increase about 0.15 with the mutation in the acceptor splice site
when compared to the reference. The percentages of A’s and G’s
in the +3 and +5 positions in the donor splice site increase 0.3
and 0.15, respectively. This type of sequence motif resembles the
consensus sequence in known donor and acceptor splice sites,
suggesting the mechanism by which splicing scores increase. In
addition, we found 33 events in which the new exons induce a
frameshift, which leads to the truncation of the canonical protein
transcript in several genes, including five in cancer-related
genes21, namely, ATRX, STK11, MAP4K3, MDM2, and MAX.
Four complex events involve concurrent exon shrinkage and the
inclusion of a new exon, which occur in the UTR or IGR.
We annotated 228 splice-creating mutations with DNA variant
allele fraction (VAF) and JAF values and their chromosome
positions (Supplementary Fig. 4). We observe wide VAF and JAF
variances, with all sites having values of at least 0.05 in both and
averages of 0.36 and 0.37, respectively. There is no correlation
between VAF and JAF values (Pearson’s coefficient 0.028), with
some genes, such as ETV6 and DNER, showing low VAF values
(0.08 and 0.15, respectively), but relatively high JAF values (0.33
and 1.0, respectively). Other genes, such asMAP2K2 and FOCAD,
have high VAF and JAF values, suggesting that the splice
alteration is highly expressed and may have significant impact on
gene function. The lack of correlation between VAF, which
reflects sample purity, and JAF suggests that JAF is a reasonable
indicator of splice junction strength. We also observed that some
mutations affect more than one gene. For instance, we found one
RPL32-CAND2 fusion transcript caused by cryptic splice sites
activated by a 3′-UTR mutation in CAND2 (Supplementary
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Fig. 2 Category and distribution of nc-SCMs from TCGA WGS data. a Schematics and counts of mutation-induced splicing events in seven different
classifications. The new exon category is subdivided into first, middle, and last, depending on the location of the new exon. The complex event is a
combination of multiple events, for example, exon extension and new exon. b Types and counts of splice forms in different non-coding regions. c
Distribution of intron sizes (log 10 scale) across different categories. The p value is from the Wilcoxon’s rank-sum test, two-sided. Source data are provided
as a Source Data file.
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the last coding exon of RPL32 by skipping its stop codon and
fusing the transcript with a partial 3′-UTR of CAND2.
Effects of non-coding splice-creating mutations on protein
sequences. The 228 non-coding splice-creating mutations are
found in 219 genes that are widely distributed across the genome
and of which 17 are associated with cancer, as reported by Lu
et al.21. We observe a significant overrepresentation of nc-SCMs
in cancer genes, including NFE2L2, CDKN2B, FUBP1, MAP2K2,
TBX3, FCGR3A, SETD2, DNER, ETV6, USP9X,MAP4K3,MDM2,
and STK11 (p < 0.001); see “Methods.” CSPP1, STK11, SLCO1B1,
NSMCE4A, and MAP4K3 contain two splice-creating mutations
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Fig. 3 Characterization of nc-SCMs from TCGA WGS data. a Frequency distribution of the distance from mutations to splice sites and splicing score
comparison between the reference and mutant primary splice sites for donors and acceptors. Blue and red colors represent introns and exons, respectively. b Splice
score distribution of new exon splice sites. Red arrows represent negative changes in score, blue arrows represent positive changes in score, and dots represent
little to no changes in score (change <0.5). Arrow length is proportional to the magnitude of the change. c Comparison of primary splice score before and after
mutation, the activated mate score in new exons, and the score of 300 random control sites. Source data are provided as a Source Data file.
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For genes harboring non-coding mutations leading to alter-
native splice forms, we investigated the impact of the splice sites
on gene expression, finding that 30 genes (>10%) with such sites
are expression outliers (“Methods”), with 3 in the lower tail
(STK11, PPIL2, and HERC2) and 27 in the upper tail (e.g.,
SLCO1B1, PNPLA7, TFR2, TMEM10B, TNFRSF11A, and
CAND2) (Supplementary Fig. 6a). We note that these expression
outliers did not pass the conventional false-discovery rate (FDR)
<0.05 cut-off; see “Methods.” The three events associated with
low expression are frameshift or truncation events. We note that
the ratio of expression outliers may be underestimated due to the
limited control sample sets with both WGS and RNA-Seq data.
Notably, two proximal G > A intronic mutations in STK11
from a head–neck cancer sample introduce a off-frame 130-bp
exon between exons 5 and 6 (Fig. 4), which was also observed in
previous study13. This development is associated with a lower
gene expression of this tumor suppressor compared to the
controls (Supplementary Fig. 6a). Loss of STK11 function was
found to be associated with the metastasis in various cancer types,
such as lung and head–neck22,23. Importantly, we found that
most of the splice-altering mutations we identified in intronic
regions create new exons. For instance, a single A > G intronic
mutation inMDM2 from bladder cancer introduces a new 118-bp
exon before the last canonical exon (Fig. 4). This new exon carries
a stop codon, leading to the truncation of the protein transcript
and the loss of a RING-type zinc-finger domain. The p53-
suppressive activity of wild-type (WT) MDM2 can be inhibited
by the ribosomal protein L1124. MDM2 zinc-finger mutants,
however, can escape inhibition to play important roles in tumor
progression23. In another example, an intergenic C > G mutation
2166 bp from the 3′-UTR of NFE2L2 in a lung cancer case leads
to a new junction that pairs with a site embedded in the start of
the last exon of NFE2L2 (Fig. 4), potentially disrupting NFE2L2/
KEAP1 interaction. Dysfunctional NFE2L2 and KEAP1 interac-
tion was found to be an activating factor for NFE2L2 oncogenic
function in lung cancer25. This splice alteration results in the loss
of most of the transcript of the last exon and the mutant
transcript has >10 RNA-supporting reads for the junction
(Supplementary Data 1). These examples illustrate potential
oncogenic effects of these non-coding mutations through altered
splicing.
Experimental validation of non-coding splice-creating muta-
tions from 9494 TCGA exome data. The wingspan of exome
probes from TCGA contains non-coding regions, which are close
to exon boundary such as 5′- and 3′-UTRs and introns. To fur-
ther investigate the dynamics of nc-SCMs, we performed
69,232,000 69,234,000



























Fig. 4 IGV schematics ofMDM2, NFE2L2, and STK11 splicing patterns. Sequence reads visualized in IGV supporting the junctions of exon-creating events
for MDM2, NFE2L2, and STK11. Red vertical lines indicate mutation positions. Source data are provided as a Source Data file.
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additional large-scale discovery from a much more substantial
cohort, 9494 TCGA tumor exomes across 33 cancer types. We
extracted non-coding mutations from the unfiltered MC3 MAF
file and ran MiSplice on these mutations (“Methods”). We found
389 nc-SCMs, of which 369 passed manual review with a 5%
false-positive rate (Supplementary Data 2). Figure 5a shows the
splice scores before and after mutations for alternative splice site
(AltSS). In general, SCMs result in an increase of splice score of
AltSSs: 57% of SCMs increase the splice score of AltSS, 33% of
SCMs show comparable splice score, and only 10% of SCMs
shows a reverse trend.
Supplementary Figure 6b shows 57 genes with nc-SCMs, which
are expression outliers, 9 and 48 of which are in low and high
tails, respectively. Supplementary Figure 6b shows 26 nc-SCMs
residing in cancer genes across 15 cancer types, namely, AKT2,
ARAF, ARFRP1, ARID1B, ATP5B, BCOR, BUB1B, CDH1,
CDKN1B, COL7A1, DNMT3A, EP300, ERBB3, ERCC2, FLCN,
FUBP1, KMT2B, MALAT1, MAP3K1, MBD1, PBRM1, PTEN,
RPL22, SMAD4, SMARCNB1, and TP53. We note that these
expression outliers did not pass the FDR <0.05 cut-off; see
“Methods.”
We used an established mini-gene assay (“Methods”) to
experimentally examine the splicing alterations generated by five
selected nc-SCMs in cancer-related genes21, namely, EP300,
BCOR, DNMT3A, KMT2B, and MAP3K1 (Fig. 6a), which play
important roles in cancer initialization and progression. The
additional band in the mutant product at ~235 bp represents
endogenous exons in the pCAS2.1 plasmid without the mutant
exon. As shown in Fig. 6a, often with this assay, if the alternative
mutant splice site is not strong enough, we see multiple
alternatively spliced products for some of the mutant constructs.
This is an expected observation with the pCAS2.1 plasmid and
the mini-gene splicing assay, since the endogenous exons have
very strong splice sites16. Overall, we validated four splicing
alterations, DMNT3A being the exception, for a suggested 80%
validation rate. The results of Sanger sequencing confirmation of
reverse transcription-polymerase chain reaction (RT-PCR) of
EP300, BCOR, KMT2B, and MAP3K1 mutants can be found in
Supplementary Figs. 7–10, which support the extended/shrunken
exons created by intronic mutations. Taken together with a
previous study of ours on coding SCMs that showed high
validation rate, the mini-gene result is mostly consistent with the
predicted result of the MiSplice pipeline for both coding and non-
coding SCMs. Figure 6b shows the IGV diagrams of alternative
splicing products resulting from intronic mutations in EP300,
KMT2B, MAP3K1, and BCOR. The intronic mutations of EP300
and KMT2B, which are 10 and 8 bp away from the nearest exon,
respectively, create cryptic AG splice sites due to the T -> G
mutations. The result is exon extension and generation of in-
frame and frameshifting products, respectively. In addition,
Fig. 6b shows that intronic mutations close to the acceptor AG
and donor GT sites weaken the canonical splice sites and result in
the AltSSs, which produce a 29-bp exon extension in MAP3K1
and a 9-bp exon shrinkage in BCOR.
Discussion
Here, we applied MiSplice to detect non-coding splice-site
creating mutation. Benchmark tests on simulated data show
MiSplice has relatively high sensitivity (>0.74) when given cov-
erages of >20× for junctions, with manual review showing com-
parable specificity of about 0.77. Application of the pipeline to
TCGA WGS and TCGA WES mutation data and RNA-Seq data
highlighted 562 mutation-induced splicing alterations in non-
coding regions of the genome. Analysis shows that mutations





























































































Fig. 5 Characterization of nc-SCMs from TCGA WES data. a Comparison of splice scores between the reference and mutant for donors and acceptors.
The color indicates the mutation distance to the junction. b nc-SCMs found in cancer-related genes across different cancer types. Source data are provided
as a Source Data file.
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alternative canonical splice sites or favorably altering splicing
sequence context. We also found that new exon creation is the
dominant splicing alteration in non-coding regions and that
corresponding introns have a larger size compared to alternative
splicing events. In addition, we observed more cases with high
expression outliers for genes harboring nc-SCMs in both WGS
and WES data, which may reflect a decay mechanism of the
altered splice product26,27.
A notable aspect of these findings is that non-coding splice-
altering mutations lie in several cancer-associated genes, such as
ATRX, BCOR, CDKN2B, MAP3K1, MAP3K4, MDM2, SMAD4,
STK11, and TP53. For instance, two proximal G > A intronic
mutations result in a new 130-bp exon in STK11, which is
associated with lower gene expression. STK11 (or LKB1) is a
tumor suppressor gene and its loss of function is associated with
tumor metastasis in lung and head–neck cancers22,23. These
findings suggest adding analyses of splicing altering potentials in
non-coding mutations to cancer studies to ensure that these
mutations are not overlooked based on their conventional
annotations.
In conclusion, our study demonstrates that 16% of tumors
from various cancer types harbor non-coding mutations that
create alternative splice sites based on TCGA WGS data, which is
a higher figure than the 1% and 9% of tumors with nc-SCMs from
our 2018 study16 and the Shiraishi’s work18, respectively. These
findings shed further light on the oncogenic effects of splice-
creating non-coding mutations. Applying this approach more
broadly will help unveil critical non-coding mutations associated
with tumorigenesis in cancer. We anticipate that larger sample
sizes and inclusion of additional cancer types with WGS data will
lead to the discovery of more splice-creating mutations. While
recurrence is often exploited to increase statistical power, there
are only two recurrent nc-SCMs in the current study. Since lack
of recurrence seems to be a general feature of our data, we did not
consider it in the current study. The bioinformatics problem of
finding and analyzing non-coding events and identifying subsets
of contributing drivers still poses a great challenge in the field of
cancer genomics. Our observations, coupled with the fact that the
data corpus of human sequences continues its rapid expansion,
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Fig. 6 Experimental validation of nc-SCMs by the mini-gene splicing assay. a Validation of non-coding splice-site-creating mutation candidates by the
mini-gene splicing assay (“Methods”). All experiments were performed by three replicates and gave similar results (see Source Data file for the full scans).
b Integrative Genomics Viewer (IGV) screenshot of four validated mutation-induced exon extension or shrinkage events. Red vertical lines indicate the
mutation positions. Source data are provided as a Source Data file.
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clinical setting, point to the urgent need for purpose-built
bioinformatics tools that can manage the analysis of non-coding
mutations and their impact on human health and disease.
Methods
MiSplice pipeline. The MiSplice pipeline was developed to detect mutation-
induced splicing events from RNA-Seq data. It is written in Perl and uses two
standard tools, SAMtools and MaxEntScan. The pipeline is fully automated and
can run multiple jobs in parallel on a compute cluster. It consists of the following
controller, processing, and helper modules:
● Top-level controller module—orchestrating execution: A maf file is split into
multiple smaller files, each containing a subset of mutations (the default
setting of 200 was used here) in order to process these in parallel on a compute
cluster. The top-level routine handles the parceling task, LSF job queuing, and
management of individual processing steps below.
● Processing module 1—junction discovery: A search is executed for splice
junctions within N= 20 bp of each subject mutation having at least M=
5 supporting reads (see minimum information power calculation below), each
with mapping quality Q ≥ 20. Canonical junctions are then filtered using the
Ensembl 37.75 database. We selected 20 bp as a cut-off since it is the farthest
distance from the splice junction in a splice region. A comparable calculation
for the number of supporting reads is made for the above cryptic splice sites in
control samples without mutations and this information is later passed to
processing module 4.
● Processing module 2—known junctions/polymorphic genes: Cryptic sites that
fall within polymorphic gene loci, for example, HLA, or those proximal to
known junctions are removed.
● Processing module 3—coverage/JAF: Sites failing either a heuristic ranking
threshold, that is, having <5% of reads supporting the junction, or (optionally)
sites failing a proportion test of number of reads at the genomic location
supporting the junction of interest and FDR correction are filtered out.
● Processing module 4—case/control: Further filtering of cryptic sites is done by
comparing the supporting reads in control samples. The final reported cryptic
sites must stand as the top k= 5% for the number of supporting reads in the
case (with mutation).
● Helper module—scoring: Splicing scores for the cryptic splice sites are
calculated using MaxEntScan.
● Helper module—read counting: Read depth of each cryptic splice site is
calculated and reported by SAMtools.
Simulation for estimating sensitivity. Because there is not yet a ground truth set
for the type of splice alterations examined here, sensitivity is more difficult to
estimate than specificity, the latter being a by-product of the manual review pro-
cess. We sought to estimate the sensitivity via constructing a simulated truth set.
Genomic sequences of length 106 bp were generated in silico in FASTA format with
an expected GC (guanine–cytosine) fraction of 40%. Sequences for each gene were
simulated with 100 exons, with the lengths of each exon and intron being picked
randomly within the ranges of 15–600 and 100–1000, respectively. Transcripts
were formed by appending exon sequences in that gene, adding 3′- and 5′-UTRs
and a poly(A) tail. Exon extensions were simulated by extending the exon length to
5′ or 3′ ends by a defined number of base pairs ranging from 5 to 50 bp. Sequence
reads of 75 bp were then simulated by picking random positions within the tran-
script, with nucleotides recapitulating the reference sequence at a rate specified by
Q= 75 base quality, and substitution rate of 0.001. Simulation of deletions and
insertions was omitted, as these are not primarily characteristic of Illumina data.
Mixed simulated data were generated by combining canonical exon transcripts
with exon extension transcripts at fractions ranging from 0.1 to 0.5.
Proportion test. An alternative to the heuristic ranking is using a binomial pro-
portion test by estimating the Bernoulli probability that any arbitrarily selected
read would support a site. This value can be used to filter sites based on whether
the number of supporting reads for a given site is significantly higher than expected
by chance. Standard Benjamini–Hochberg FDR multiple test correction can sub-
sequently be applied to across the sites.
Expression outlier analysis. To investigate if genes harboring splice sites are
expression outliers, we used Tukey’s standard formula to quantify an outlier score:
Outlier score ¼ x  Q3ð Þ=IQR for upper tail and x  Q1ð Þ=IQR for low tail; ð1Þ
where IQR is the interquartile range, Q1 and Q3 are the first and third quartiles,
respectively, and x is the RSEM (RNA-Seq by expectation maximization) value in a
log 2 scale. In the current study, genes with an outlier score >1.5 or <−1.5 are
considered to be expression outliers. We converted outlier score to p value and did
the Benjamini–Hochberg FDR multiple test correction by using R package.
Fisher’s exact test. We calculated p values for the overrepresentation of nc-SCMs
in cancer genes by Fisher’s exact test. Based on Ensemble 75 data, there are about
20,000 genes in the human genome, of which 624 are cancer-related genes21. We
found that 228 nc-SCMs are widely distributed in 219 genes, roughly each gene
having a unique nc-SCM, of which 17 are cancer-related genes. We created the







, where n1 and n2 are the numbers of non-
cancer and cancer-related genes with nc-SCMs, and t1 and t2 are respective tallies
from the overall genome. The table yields a two-sided Fisher tailed p value is <0.01.
Power assessments. A primary issue in all detection algorithms is the minimum
information required to be able to discern a real signal. In keeping with the
binomial approach of assessing numbers of supporting reads versus WT reads for a
candidate site, we estimate required read depth using the standard Gaussian-
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where R is the required number of covering reads, Z1−α and Z1−β are the respective
type I (false-positive) and type II (power) Z-scores, and J0 and J1 are the null and
alternative JAFs. It is common to select type I and II Z values of 1.645 and 0.84,
respectively, representing 5% false positive and 80% power. Figure 1b was plotted
assuming a null JAF of 5%. The generally deep coverage can result in higher
tendencies for artifactual alignments, which can be misinterpreted as supporting
evidence. For 200× depth, the expected number of artifacts is 200 × 10−Q/10= 2
reads, assuming average quality of Q= 20. We therefore added a minimum
requirement of five junction supporting reads based on the Poisson tail probability
that having such a combination of artifacts purely by chance would be only ~5%.
Long intron bias estimation. New exon creation depends upon finding both a 9-
nucleotide donor and a 23-nucleotide acceptor, a joint event of 32 nucleotides
having a Bernoulli probability of 1/432 ≈ 10−19. In addition, within an intron of
length L, the donor and acceptor must be separated from each other by a distance E
that is characteristic of exon size, which can occur in roughly L – E – 31 ways. If we
omit consideration of the mutation itself, the probability of realizing the conditions
for new exon creation is then proportional to 1− (1− 10−19)L− E− 31 ≈ 1− exp
[−10−19 (L− E− 31)] ≈ 10−19 (L− E− 31). The last simplification stems from
expanding e−x, where x is small and only the first term is retained. It implies that
bias of long introns versus shorter introns, LL and LS, respectively, can be quan-
tified by the ratio (LL− E− 31)/(LS− E− 31). For the types of smaller introns
found here, this ratio is approximately LL/LS ≈ 30,000/3000, indicating a roughly
10-fold bias toward large introns in the data we examined. However, this model
also implies an additional bias in the form of an “edge effect” against larger exons
arising within smaller introns, for example, for E= 200 and LS= 1000 the ratio is
~40-fold. Such cases would be expected only in rare instances.
Splice site score estimation. For each cryptic splice site and nearby canonical
splice site, the corresponding nucleotide sequences were first extracted for both the
mutant and reference sequences (9 mer and 23 mer for donor and acceptor sites,
respectively). Their splice scores as potential donor or acceptor sites were then
estimated using MaxEntScan with a maximum entropy scoring model.
IGV manual review. As described above, the MiSplice pipeline uses control and
case comparison to remove cryptic sites, which were found in samples without
mutations. In the manual review step, we further looked into the mutations at the
RNA level by IGV to further remove false positives. We specifically double-checked
that at least five reads support the junction. Also, for spliced-in mutations, which
are included in the newly created exon from the cryptic site (see the MAP3K1
chr5:56179340 intronic mutation in Fig. 6b), we double-checked whether reads,
which cover the cryptic site and mutation site, contain the specific mutation. If not,
we assigned it as a false positive and removed it from the downstream analysis.
Mini-gene splicing assay. Exons and flanking sequences from HEK293T genomic
DNA are amplified using primers carrying restriction enzyme sites for BamH1 and
MluI. Amplified sequences are subject to NucleoSpin PCR Cleanup (Macherey-
Nagel) or DNA Clean and Concentrator-5 Kit (Zymo Research) and digested with
BamHI and MluI. T4 DNA ligase (NEB) was used to ligate the digested pCAS2.1





TTTCCAGCTTGCCGAC AACCAACTCAACAACCAAT.” The two bold and
underlined “GG” nucleotides are the boundary between the two endogenous exons
in the pCAS2.1 plasmid, which is the inserted position of the exon of WT or
mutant. Mutations were introduced via Q5 Site-Directed Mutagenesis (NEB). Both
the inserted amplified sequence and the mutation of interest were confirmed by
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sequencing. Plasmids are transiently transfected with Lipofectamine 2000 (Thermo
Fisher Scientific) into HEK293T cells. After 24 h post transfection, cDNA was
synthesized using 2–3 μg of total RNA with the Superscript III First-Strand
Synthesis System (Thermo Fisher Scientific) and Oligo(dT)20 was used for prim-
ing. cDNA amplification was performed with the following primers: pCAS-KO1-
(5′-TGACGTCGCCGCCCAT-3′) and pCAS-R (5′-ATTGGTTGTTGAGTTGGT
TGTCGG-3′). Splicing patterns were visualized on a 4% agarose gel with ethidium
bromide. Finally, each alternative band on the gel was purified for sequencing using
Qiaquick Gel Extraction Kit (Qiagen) to validate mutant and WT predictions16. All
primer sequences used in this study can be found in Supplementary Table 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The WGS mutation data for 790 TCGA samples with RNA-Seq were obtained from the
International Cancer Genome Consortium (ICGC) at https://www.synapse.org/#!
Synapse:syn7118450 (version 12-Oct-2016). We removed one outlier cancer type
(DLBC) with only seven samples, which reduced the WGS samples set from 790 to 783;
see Supplementary Fig. 2. The full name of each cancer type included in the current study
can be found at https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-
abbreviations. The controlled-accessed WES mutation data were downloaded from GDC
(https://gdc.cancer.gov/about-data/publications/mc3-2017). The ISB-CGC (https://isb-
cgc.appspot.com) access of the TCGA RNA-Seq bam corpus was granted through tcga-
phs000178-controlled credential. The TCGA RNA-Seq alignments used in this study
were generated by using MapSplice (https://academic.oup.com/nar/article/38/18/e178/
1068935) against the hg19 reference genome. Details needed to replicate TCGA RNA-Seq
bam file can be found at https://webshare.bioinf.unc.edu/public/mRNAseq_TCGA/. We
also obtained gene expression data (RSEM) from the Broad firehose collection (http://
gdac.broadinstitute.org/runs/stddata__2016_01_28/) across 33 TCGA cancer types.
Ensembl 37.75 database can be downloaded from ftp://ftp.ensembl.org/pub/release-75/
gtf/homo_sapiens/. All other data supporting the findings of this study are available from
the corresponding author upon request. Source data are provided with this paper.
Code availability
MiSplice is written in Perl and is freely available at https://github.com/ding-lab/Misplice
under the GNU general public license. MiSplice uses several independent tools and
packages, including SAMtools and MaxEntScan, all of which are likewise freely available,
but which must be obtained independently from their respective developers. The
MiSplice documentation contains complete instructions for obtaining and linking these
applications into the MiSplice pipeline.
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